Preventive effect and prognosis of carbetocin on postpartum hemorrhage

Yan Cui; Jialei Zhu

doi:10.18282/po4713

Yan Cui Obstetrics and Gynecology Hospital of Fudan University
Jialei Zhu ^* Obstetrics and Gynecology Hospital of Fudan University, East China Umiversityofscience Andtechnology School of Pharmacy

Article ID: 4713

DOI: https://doi.org/10.18282/po4713

Keywords: postpartum hemorrhage; Carbetocin; Preventive effect; prognosis

Abstract

Objective: To investigate the clinical value of carbetocin in the treatment of postpartum hemorrhage (PPH) in the hospital. Methods: From 2018 to 2022, a total of 38948 high-risk parturients admitted to the hospital were enrolled in the study. All parturients were treated with carbetocin and the therapeutic results were compared and analyzed. Results: All the parturients suffered postpartum bleeding and their newborns were in good condition. Compared with the prenatal period, the postpartum hemoglobin (Hb), red blood cell volume (RCV) and red blood cell count (RBC) were both decreased after postpartum through vaginal delivery, regrettably there was no statistical difference (P > 0.05). In addition, the total incidence of adverse reactions was 0.1% (11/38948), which was low. Furthermore, we found that the annual dose of carbetocin were decreased year by year after 2019, which may be correlated with the decrease in the birth rate of newborns in China. Conclusion: The use of carbetocin alleviated the clinical indications of PPH in women undergoing vaginal delivery to a certain extent. However, there was no significant difference between prenatal and postnatal biomarkers.